RT Journal Article SR Electronic T1 Cost-effectiveness of vitamin D3 supplementation in older adults with vitamin D deficiency in Ireland JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.10.31.21265715 DO 10.1101/2021.10.31.21265715 A1 Lacey, Laurence F. A1 Armstrong, David J. A1 Royle, Emily A1 Magee, Pamela J. A1 Pourshahidi, L. Kirsty A1 Ray, Sumantra A1 Strain, J. J. A1 McSorley, Emeir M. YR 2021 UL http://medrxiv.org/content/early/2021/11/01/2021.10.31.21265715.abstract AB Background This study investigated the cost-effectiveness of vitamin D3 supplementation in older adults in Ireland, with year-round vitamin D deficiency (serum 25-hydroxyvitamin D concentration <30 nmol/L) (13% of Irish adults), from the perspective of the Health Service Executive (HSE).Methods Three age groups were investigated: (1) ≥50 years, (2) ≥60 years, (3) ≥70 years. Based on the clinical literature, vitamin D3 supplementation may (1) decrease all-cause mortality by 7%, and (2) reduce hip fractures by 16%, and non-hip fractures by 20%. A discount rate of 4% was applied to life years and QALYs gained. The annual healthcare costs per patient used in the model are based on the average annual health resource use over the 5-year time horizon of the model.Results The cost/QALY estimates in all three age groups are below the usually acceptable cost-effectiveness threshold of €20,000/QALY. The most cost-effective and least costly intervention was in adults ≥70 years. For this age group, the average annual costs and outcomes would be approx. €6.2 million, 1,043 QALYs gained, with a cost/QALY of approx. €6,000. The results are most sensitive to the mortality risk reduction following vitamin D3 supplementation.Conclusion The cost-effectiveness of vitamin D3 supplementation is most robust in adults ≥70 years. Clinical uncertainty in the magnitude of the benefits of vitamin D3 supplementation could be further addressed by means of (1) performing a clinical research study or (2) conducting a pilot/regional study, prior to reaching a decision to invest in a full nationwide programme.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe methodology used is described in detail in the manuscript. The health economic analysis is available as a MS Excel spreadsheet